2021-22 Courses


Stanford Advisees


All Publications


  • Integrating explanation and prediction in computational social science. Nature Hofman, J. M., Watts, D. J., Athey, S., Garip, F., Griffiths, T. L., Kleinberg, J., Margetts, H., Mullainathan, S., Salganik, M. J., Vazire, S., Vespignani, A., Yarkoni, T. 2021

    Abstract

    Computational social science is more than just large repositories of digital data and the computational methods needed to construct and analyse them. It also represents a convergence of different fields with different ways of thinking about and doing science. The goal of this Perspective is to provide some clarity around how these approaches differ from one another and to propose how they might be productively integrated. Towards this end we make two contributions. The first is a schema for thinking about research activities along two dimensions-the extent to which work is explanatory, focusing on identifying and estimating causal effects, and the degree of consideration given to testing predictions of outcomes-and how these two priorities can complement, rather than compete with, one another. Our second contribution is to advocate that computational social scientists devote more attention to combining prediction and explanation, which we call integrative modelling, and to outline some practical suggestions for realizing this goal.

    View details for DOI 10.1038/s41586-021-03659-0

    View details for PubMedID 34194044

  • Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. eLife Koenecke, A., Powell, M., Xiong, R., Shen, Z., Fischer, N., Huq, S., Khalafallah, A. M., Trevisan, M., Sparen, P., Carrero, J. J., Nishimura, A., Caffo, B., Stuart, E. A., Bai, R., Staedtke, V., Thomas, D. L., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., Zhou, S., Bettegowda, C., Konig, M. F., Mensh, B. D., Vogelstein, J. T., Athey, S. 2021; 10

    Abstract

    In severe viral pneumonia, including Coronavirus disease 2019 (COVID-19), the viral replication phase is often followed by hyperinflammation, which can lead to acute respiratory distress syndrome, multi-organ failure, and death. We previously demonstrated that alpha-1 adrenergic receptor (⍺1-AR) antagonists can prevent hyperinflammation and death in mice. Here, we conducted retrospective analyses in two cohorts of patients with acute respiratory distress (ARD, n = 18,547) and three cohorts with pneumonia (n = 400,907). Federated across two ARD cohorts, we find that patients exposed to ⍺1-AR antagonists, as compared to unexposed patients, had a 34% relative risk reduction for mechanical ventilation and death (OR = 0.70, p = 0.021). We replicated these methods on three pneumonia cohorts, all with similar effects on both outcomes. All results were robust to sensitivity analyses. These results highlight the urgent need for prospective trials testing whether prophylactic use of ⍺1-AR antagonists ameliorates lower respiratory tract infection-associated hyperinflammation and death, as observed in COVID-19.

    View details for DOI 10.7554/eLife.61700

    View details for PubMedID 34114951

  • PRIVATE AND SOCIAL RETURNS TO R&D AND VACCINE DEVELOPMENT Preparing for a Pandemic: Accelerating Vaccine Availability Ahuja, A., Athey, S., Baker, A., Budish, E., Castillo, J., Glennerster, R., Kominers, S., Kremer, M., Lee, J., Prendergast, C., Snyder, C. M., Tabarrok, A., Tan, B., Wiecek, W. AMER ECONOMIC ASSOC. 2021: 331-335
  • Matrix Completion Methods for Causal Panel Data Models JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION Athey, S., Bayati, M., Doudchenko, N., Imbens, G., Khosravi, K. 2021
  • Confidence intervals for policy evaluation in adaptive experiments. Proceedings of the National Academy of Sciences of the United States of America Hadad, V., Hirshberg, D. A., Zhan, R., Wager, S., Athey, S. 2021; 118 (15)

    Abstract

    Adaptive experimental designs can dramatically improve efficiency in randomized trials. But with adaptively collected data, common estimators based on sample means and inverse propensity-weighted means can be biased or heavy-tailed. This poses statistical challenges, in particular when the experimenter would like to test hypotheses about parameters that were not targeted by the data-collection mechanism. In this paper, we present a class of test statistics that can handle these challenges. Our approach is to adaptively reweight the terms of an augmented inverse propensity-weighting estimator to control the contribution of each term to the estimator's variance. This scheme reduces overall variance and yields an asymptotically normal test statistic. We validate the accuracy of the resulting estimates and their CIs in numerical experiments and show that our methods compare favorably to existing alternatives in terms of mean squared error, coverage, and CI size.

    View details for DOI 10.1073/pnas.2014602118

    View details for PubMedID 33876748

  • Market design to accelerate COVID-19 vaccine supply. Science (New York, N.Y.) Castillo, J. C., Ahuja, A., Athey, S., Baker, A., Budish, E., Chipty, T., Glennerster, R., Kominers, S. D., Kremer, M., Larson, G., Lee, J., Prendergast, C., Snyder, C. M., Tabarrok, A., Tan, B. J., Wiecek, W. 2021

    Abstract

    Build more capacity, and stretch what we already have.

    View details for DOI 10.1126/science.abg0889

    View details for PubMedID 33632897

  • Association of alpha1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark. JAMA network open Thomsen, R. W., Christiansen, C. F., Heide-Jorgensen, U., Vogelstein, J. T., Vogelstein, B., Bettegowda, C., Tamang, S., Athey, S., Sorensen, H. T. 2021; 4 (2): e2037053

    Abstract

    Importance: Alpha 1-adrenergic receptor blocking agents (alpha1-blockers) have been reported to have protective benefits against hyperinflammation and cytokine storm syndrome, conditions that are associated with mortality in patients with coronavirus disease 2019 and other severe respiratory tract infections. However, studies of the association of alpha1-blockers with outcomes among human participants with respiratory tract infections are scarce.Objective: To examine the association between the receipt of alpha1-blockers and outcomes among adult patients hospitalized with influenza or pneumonia.Design, Setting, and Participants: This population-based cohort study used data from Danish national registries to identify individuals 40 years and older who were hospitalized with influenza or pneumonia between January 1, 2005, and November 30, 2018, with follow-up through December 31, 2018. In the main analyses, patients currently receiving alpha1-blockers were compared with those not receiving alpha1-blockers (defined as patients with no prescription for an alpha1-blocker filled within 365 days before the index date) and those currently receiving 5alpha-reductase inhibitors. Propensity scores were used to address confounding factors and to compute weighted risks, absolute risk differences, and risk ratios. Data were analyzed from April 21 to December 21, 2020.Exposures: Current receipt of alpha1-blockers compared with nonreceipt of alpha1-blockers and with current receipt of 5alpha-reductase inhibitors.Main Outcomes and Measures: Death within 30 days of hospital admission and risk of intensive care unit (ICU) admission.Results: A total of 528 467 adult patients (median age, 75.0 years; interquartile range, 64.4-83.6 years; 273 005 men [51.7%]) were hospitalized with influenza or pneumonia in Denmark between 2005 and 2018. Of those, 21 772 patients (4.1%) were currently receiving alpha1-blockers compared with a population of 22 117 patients not receiving alpha1-blockers who were weighted to the propensity score distribution of those receiving alpha1-blockers. In the propensity score-weighted analyses, patients receiving alpha1-blockers had lower 30-day mortality (15.9%) compared with patients not receiving alpha1-blockers (18.5%), with a corresponding risk difference of -2.7% (95% CI, -3.2% to -2.2%) and a risk ratio (RR) of 0.85 (95% CI, 0.83-0.88). The risk of ICU admission was 7.3% among patients receiving alpha1-blockers and 7.7% among those not receiving alpha1-blockers (risk difference, -0.4% [95% CI, -0.8% to 0%]; RR, 0.95 [95% CI, 0.90-1.00]). A comparison between 18 280 male patients currently receiving alpha1-blockers and 18 228 propensity score-weighted male patients currently receiving 5alpha-reductase inhibitors indicated that those receiving alpha1-blockers had lower 30-day mortality (risk difference, -2.0% [95% CI, -3.4% to -0.6%]; RR, 0.89 [95% CI, 0.82-0.96]) and a similar risk of ICU admission (risk difference, -0.3% [95% CI, -1.4% to 0.7%]; RR, 0.96 [95% CI, 0.83-1.10]).Conclusions and Relevance: This cohort study's findings suggest that the receipt of alpha1-blockers is associated with protective benefits among adult patients hospitalized with influenza or pneumonia.

    View details for DOI 10.1001/jamanetworkopen.2020.37053

    View details for PubMedID 33566109

  • Falling living standards during the COVID-19 crisis: Quantitative evidence from nine developing countries. Science advances Egger, D., Miguel, E., Warren, S. S., Shenoy, A., Collins, E., Karlan, D., Parkerson, D., Mobarak, A. M., Fink, G., Udry, C., Walker, M., Haushofer, J., Larreboure, M., Athey, S., Lopez-Pena, P., Benhachmi, S., Humphreys, M., Lowe, L., Meriggi, N. F., Wabwire, A., Davis, C. A., Pape, U. J., Graff, T., Voors, M., Nekesa, C., Vernot, C. 2021; 7 (6)

    Abstract

    Despite numerous journalistic accounts, systematic quantitative evidence on economic conditions during the ongoing COVID-19 pandemic remains scarce for most low- and middle-income countries, partly due to limitations of official economic statistics in environments with large informal sectors and subsistence agriculture. We assemble evidence from over 30,000 respondents in 16 original household surveys from nine countries in Africa (Burkina Faso, Ghana, Kenya, Rwanda, Sierra Leone), Asia (Bangladesh, Nepal, Philippines), and Latin America (Colombia). We document declines in employment and income in all settings beginning March 2020. The share of households experiencing an income drop ranges from 8 to 87% (median, 68%). Household coping strategies and government assistance were insufficient to sustain precrisis living standards, resulting in widespread food insecurity and dire economic conditions even 3 months into the crisis. We discuss promising policy responses and speculate about the risk of persistent adverse effects, especially among children and other vulnerable groups.

    View details for DOI 10.1126/sciadv.abe0997

    View details for PubMedID 33547077

  • POLICY LEARNING WITH OBSERVATIONAL DATA ECONOMETRICA Athey, S., Wager, S. 2021; 89 (1): 133–61

    View details for DOI 10.3982/ECTA15732

    View details for Web of Science ID 000607743600005

  • Ten Rules for Conducting Retrospective Pharmacoepidemiological Analyses: Example COVID-19 Study. Frontiers in pharmacology Powell, M., Koenecke, A., Byrd, J. B., Nishimura, A., Konig, M. F., Xiong, R., Mahmood, S., Mucaj, V., Bettegowda, C., Rose, L., Tamang, S., Sacarny, A., Caffo, B., Athey, S., Stuart, E. A., Vogelstein, J. T. 2021; 12: 700776

    Abstract

    Since the beginning of the COVID-19 pandemic, pharmaceutical treatment hypotheses have abounded, each requiring careful evaluation. A randomized controlled trial generally provides the most credible evaluation of a treatment, but the efficiency and effectiveness of the trial depend on the existing evidence supporting the treatment. The researcher must therefore compile a body of evidence justifying the use of time and resources to further investigate a treatment hypothesis in a trial. An observational study can provide this evidence, but the lack of randomized exposure and the researcher's inability to control treatment administration and data collection introduce significant challenges. A proper analysis of observational health care data thus requires contributions from experts in a diverse set of topics ranging from epidemiology and causal analysis to relevant medical specialties and data sources. Here we summarize these contributions as 10 rules that serve as an end-to-end introduction to retrospective pharmacoepidemiological analyses of observational health care data using a running example of a hypothetical COVID-19 study. A detailed supplement presents a practical how-to guide for following each rule. When carefully designed and properly executed, a retrospective pharmacoepidemiological analysis framed around these rules will inform the decisions of whether and how to investigate a treatment hypothesis in a randomized controlled trial. This work has important implications for any future pandemic by prescribing what we can and should do while the world waits for global vaccine distribution.

    View details for DOI 10.3389/fphar.2021.700776

    View details for PubMedID 34393782

  • The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19. Frontiers in medicine Rose, L., Graham, L., Koenecke, A., Powell, M., Xiong, R., Shen, Z., Mench, B., Kinzler, K. W., Bettegowda, C., Vogelstein, B., Athey, S., Vogelstein, J. T., Konig, M. F., Wagner, T. H. 2021; 8: 637647

    Abstract

    Effective therapies for coronavirus disease 2019 (COVID-19) are urgently needed, and pre-clinical data suggest alpha-1 adrenergic receptor antagonists (alpha1-AR antagonists) may be effective in reducing mortality related to hyperinflammation independent of etiology. Using a retrospective cohort design with patients in the Department of Veterans Affairs healthcare system, we use doubly robust regression and matching to estimate the association between baseline use of alpha1-AR antagonists and likelihood of death due to COVID-19 during hospitalization. Having an active prescription for any alpha1-AR antagonist (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) at the time of admission had a significant negative association with in-hospital mortality (relative risk reduction 18%; odds ratio 0.73; 95% CI 0.63-0.85; p ≤ 0.001) and death within 28 days of admission (relative risk reduction 17%; odds ratio 0.74; 95% CI 0.65-0.84; p ≤ 0.001). In a subset of patients on doxazosin specifically, an inhibitor of all three alpha-1 adrenergic receptors, we observed a relative risk reduction for death of 74% (odds ratio 0.23; 95% CI 0.03-0.94; p = 0.028) compared to matched controls not on any alpha1-AR antagonist at the time of admission. These findings suggest that use of alpha1-AR antagonists may reduce mortality in COVID-19, supporting the need for randomized, placebo-controlled clinical trials in patients with early symptomatic infection.

    View details for DOI 10.3389/fmed.2021.637647

    View details for PubMedID 33869251

  • Local Linear Forests JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS Friedberg, R., Tibshirani, J., Athey, S., Wager, S. 2020
  • Peaches, lemons, and cookies: Designing auction markets with dispersed information GAMES AND ECONOMIC BEHAVIOR Abraham, I., Athey, S., Babaioff, M., Grubb, M. D. 2020; 124: 454–77
  • The Allocation of Decision Authority to Human and Artificial Intelligence Athey, S. C., Bryan, K. A., Gans, J. S. AMER ECONOMIC ASSOC. 2020: 80–84
  • SHOPPER: A PROBABILISTIC MODEL OF CONSUMER CHOICE WITH SUBSTITUTES AND COMPLEMENTS ANNALS OF APPLIED STATISTICS Ruiz, F. R., Athey, S., Blei, D. M. 2020; 14 (1): 1–27
  • SAMPLING-BASED VERSUS DESIGN-BASED UNCERTAINTY IN REGRESSION ANALYSIS ECONOMETRICA Abadie, A., Athey, S., Imbens, G. W., Wooldridge, J. M. 2020; 88 (1): 265–96

    View details for DOI 10.3982/ECTA12675

    View details for Web of Science ID 000534143500008

  • Stable Prediction with Model Misspecification and Agnostic Distribution Shift Kuang, K., Xiong, R., Cui, P., Athey, S., Li, B., Assoc Advancement Artificial Intelligence ASSOC ADVANCEMENT ARTIFICIAL INTELLIGENCE. 2020: 4485-4492
  • The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19. medRxiv : the preprint server for health sciences Rose, L. n., Graham, L. n., Koenecke, A. n., Powell, M. n., Xiong, R. n., Shen, Z. n., Kinzler, K. W., Bettegowda, C. n., Vogelstein, B. n., Athey, S. n., Vogelstein, J. T., Konig, M. F., Wagner, T. H. 2020

    Abstract

    Effective therapies for coronavirus disease 2019 (COVID-19) are urgently needed, and preclinical data suggest alpha-1 adrenergic receptor antagonists (α 1 -AR antagonists) may be effective in reducing mortality related to hyperinflammation. Using a retrospective cohort design with patients in the Department of Veterans Affairs healthcare system, we use doubly robust regression and matching to estimate the association between use of α 1 -AR antagonists at time of hospitalization and likelihood of death due to COVID-19 during an inpatient stay. Having an active prescription for an α 1 -AR antagonist (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) at the time of admission had a significant negative association with in-hospital mortality (relative risk reduction 14%; odds ratio 0.75; 95% CI 0.66 to 0.86; p ≤ 0.001). These effects were also found in an expanded cohort of suspected COVID-19 patients, supporting the need for clinical trials.

    View details for DOI 10.1101/2020.12.18.20248346

    View details for PubMedID 33398294

    View details for PubMedCentralID PMC7781337

  • Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. The Journal of clinical investigation Konig, M. F., Powell, M. A., Staedtke, V. n., Bai, R. Y., Thomas, D. L., Fischer, N. M., Huq, S. n., Khalafallah, A. M., Koenecke, A. n., Xiong, R. n., Mensh, B. n., Papadopoulos, N. n., Kinzler, K. W., Vogelstein, B. n., Vogelstein, J. T., Athey, S. n., Zhou, S. n., Bettegowda, C. n. 2020

    Abstract

    Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases.

    View details for DOI 10.1172/JCI139642

    View details for PubMedID 32352407

  • Computational social science: Obstacles and opportunities. Science (New York, N.Y.) Lazer, D. M., Pentland, A. n., Watts, D. J., Aral, S. n., Athey, S. n., Contractor, N. n., Freelon, D. n., Gonzalez-Bailon, S. n., King, G. n., Margetts, H. n., Nelson, A. n., Salganik, M. J., Strohmaier, M. n., Vespignani, A. n., Wagner, C. n. 2020; 369 (6507): 1060–62

    View details for DOI 10.1126/science.aaz8170

    View details for PubMedID 32855329

  • Economists (and Economics) in Tech Companies JOURNAL OF ECONOMIC PERSPECTIVES Athey, S., Luca, M. 2019; 33 (1): 209–30
  • Comment on: "The Blessings of Multiple Causes" by Yixin Wang and David M. Blei JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION Athey, S., Imbens, G. W., Pollmann, M. 2019; 114 (528): 1602–4
  • GENERALIZED RANDOM FORESTS ANNALS OF STATISTICS Athey, S., Tibshirani, J., Wager, S. 2019; 47 (2): 1148–78

    View details for DOI 10.1214/18-AOS1709

    View details for Web of Science ID 000455476800018

  • Balanced Linear Contextual Bandits Dimakopoulou, M., Zhou, Z., Athey, S., Imbens, G., AAAI ASSOC ADVANCEMENT ARTIFICIAL INTELLIGENCE. 2019: 3445–53
  • Machine Learning Methods That Economists Should Know About ANNUAL REVIEW OF ECONOMICS, VOL 11, 2019 Athey, S., Imbens, G. W., Aghion, P., Rey, H. 2019; 11: 685–725
  • Approximate residual balancing: debiased inference of average treatment effects in high dimensions JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY Athey, S., Imbens, G. W., Wager, S. 2018; 80 (4): 597–623

    View details for DOI 10.1111/rssb.12268

    View details for Web of Science ID 000442217900001

  • Estimating Heterogeneous Consumer Preferences for Restaurants and Travel Time Using Mobile Location Data Athey, S., Blei, D., Donnelly, R., Ruiz, F., Schmidt, T. AMER ECONOMIC ASSOC. 2018: 64–67
  • The Impact of Consumer Multi-homing on Advertising Markets and Media Competition MANAGEMENT SCIENCE Athey, S., Calvano, E., Gans, J. S. 2018; 64 (4): 1574–90
  • The value of information in monotone decision problems RESEARCH IN ECONOMICS Athey, S., Levin, J. 2018; 72 (1): 101–16
  • Exact p-Values for Network Interference JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION Athey, S., Eckles, D., Imbens, G. W. 2018; 113 (521): 230–40
  • Stable Prediction across Unknown Environments Kuang, K., Cui, P., Athey, S., Xiong, R., Li, B., ACM ASSOC COMPUTING MACHINERY. 2018: 1617–26
  • Learning in Games with Lossy Feedback Zhou, Z., Mertikopoulos, P., Athey, S., Bambos, N., Glynn, P., Ye, Y., Bengio, S., Wallach, H., Larochelle, H., Grauman, K., CesaBianchi, N., Garnett, R. NEURAL INFORMATION PROCESSING SYSTEMS (NIPS). 2018
  • Estimation and Inference of Heterogeneous Treatment Effects using Random Forests JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION Wager, S., Athey, S. 2018; 113 (523): 1228–42
  • Estimating Average Treatment Effects: Supplementary Analyses and Remaining Challenges AMERICAN ECONOMIC REVIEW Athey, S., Imbens, G., Pham, T., Wager, S. 2017; 107 (5): 278-281
  • Yuliy Sannikov: Winner of the 2016 Clark Medal JOURNAL OF ECONOMIC PERSPECTIVES Athey, S., Skrzypacz, A. 2017; 31 (2): 237-255
  • The State of Applied Econometrics: Causality and Policy Evaluation JOURNAL OF ECONOMIC PERSPECTIVES Athey, S., Imbens, G. W. 2017; 31 (2): 3-32

    View details for DOI 10.1257/jep.31.2.3

    View details for Web of Science ID 000403753100001

  • Beyond prediction: Using big data for policy problems. Science (New York, N.Y.) Athey, S. n. 2017; 355 (6324): 483–85

    Abstract

    Machine-learning prediction methods have been extremely productive in applications ranging from medicine to allocating fire and health inspectors in cities. However, there are a number of gaps between making a prediction and making a decision, and underlying assumptions need to be understood in order to optimize data-driven decision-making.

    View details for PubMedID 28154050

  • Context Selection for Embedding Models Liu, L., Ruiz, F. R., Athey, S., Blei, D. M., Guyon, Luxburg, U. V., Bengio, S., Wallach, H., Fergus, R., Vishwanathan, S., Garnett, R. NEURAL INFORMATION PROCESSING SYSTEMS (NIPS). 2017
  • Structured Embedding Models for Grouped Data Rudolph, M., Ruiz, F., Athey, S., Blei, D., Guyon, Luxburg, U. V., Bengio, S., Wallach, H., Fergus, R., Vishwanathan, S., Garnett, R. NEURAL INFORMATION PROCESSING SYSTEMS (NIPS). 2017
  • Recursive partitioning for heterogeneous causal effects PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Athey, S., Imbens, G. 2016; 113 (27): 7353-7360

    Abstract

    In this paper we propose methods for estimating heterogeneity in causal effects in experimental and observational studies and for conducting hypothesis tests about the magnitude of differences in treatment effects across subsets of the population. We provide a data-driven approach to partition the data into subpopulations that differ in the magnitude of their treatment effects. The approach enables the construction of valid confidence intervals for treatment effects, even with many covariates relative to the sample size, and without "sparsity" assumptions. We propose an "honest" approach to estimation, whereby one sample is used to construct the partition and another to estimate treatment effects for each subpopulation. Our approach builds on regression tree methods, modified to optimize for goodness of fit in treatment effects and to account for honest estimation. Our model selection criterion anticipates that bias will be eliminated by honest estimation and also accounts for the effect of making additional splits on the variance of treatment effect estimates within each subpopulation. We address the challenge that the "ground truth" for a causal effect is not observed for any individual unit, so that standard approaches to cross-validation must be modified. Through a simulation study, we show that for our preferred method honest estimation results in nominal coverage for 90% confidence intervals, whereas coverage ranges between 74% and 84% for nonhonest approaches. Honest estimation requires estimating the model with a smaller sample size; the cost in terms of mean squared error of treatment effects for our preferred method ranges between 7-22%.

    View details for DOI 10.1073/pnas.1510489113

    View details for Web of Science ID 000379021700039

    View details for PubMedID 27382149

    View details for PubMedCentralID PMC4941430

  • A Measure of Robustness to Misspecification AMERICAN ECONOMIC REVIEW Athey, S., Imbens, G. 2015; 105 (5): 476-480
  • Machine Learning and Causal Inference for Policy Evaluation Athey, S., Assoc Comp Machinery ASSOC COMPUTING MACHINERY. 2015: 5-6
  • Dynamics of Open Source Movements JOURNAL OF ECONOMICS & MANAGEMENT STRATEGY Athey, S., Ellison, G. 2014; 23 (2): 294-316

    View details for DOI 10.1111/jems.12053

    View details for Web of Science ID 000333811500003

  • AN EFFICIENT DYNAMIC MECHANISM ECONOMETRICA Athey, S., Segal, I. 2013; 81 (6): 2463-2485

    View details for DOI 10.3982/ECTA6995

    View details for Web of Science ID 000326878900007

  • Set-Asides and Subsidies in Auctions AMERICAN ECONOMIC JOURNAL-MICROECONOMICS Athey, S., Coey, D., Levin, J. 2013; 5 (1): 1-27

    View details for DOI 10.1257/mic.5.1.1

    View details for Web of Science ID 000314063400001

  • Designing efficient mechanisms for dynamic bilateral trading games 119th Annual Meeting of the American-Economic-Association Athey, S., Segal, I. AMER ECONOMIC ASSOC. 2007: 131–36
  • Identification and inference in nonlinear difference-in-differences models ECONOMETRICA Athey, S., Imbens, G. W. 2006; 74 (2): 431-497
  • The optimal degree of discretion in monetary policy ECONOMETRICA Athey, S., Atkeson, A., Kehoe, P. J. 2005; 73 (5): 1431-1475
  • Collusion and price rigidity REVIEW OF ECONOMIC STUDIES Athey, S., Bagwell, K., Sanchirico, C. 2004; 71 (2): 317-349
  • Identification of standard auction models ECONOMETRICA Athey, S., Haile, P. A. 2002; 70 (6): 2107-2140
  • The impact of information technology on emergency health care outcomes Conference on the Industrial-Organization-of-Medical-Care Athey, S., Stern, S. BLACKWELL PUBLISHING. 2002: 399–432

    Abstract

    We analyze the productivity of information technology in emergency response systems. "Enhanced 911" (E911) is information technology that links caller identification to a location database and so speeds up emergency response. We assess the impact of E911 on health outcomes using Pennsylvania ambulance and hospital records between 1994 and 1996, a period of substantial adoption. We find that as a result of E911 adoption, patient health measured at the time of ambulance arrival improves, suggesting that E911 speeds up emergency response. Further analysis using hospital discharge data shows that E911 reduces mortality and hospital costs.

    View details for Web of Science ID 000179256800004

    View details for PubMedID 12585298

  • Monotone comparative statics under uncertainty QUARTERLY JOURNAL OF ECONOMICS Athey, S. 2002; 117 (1): 187-223
  • Optimal collusion with private information RAND JOURNAL OF ECONOMICS Athey, S., Bagwell, K. 2001; 32 (3): 428-465
  • Organizational design: Decision rights and incentive contracts 113th Annual Meeting of the American-Economics-Association Athey, S., Roberts, J. AMER ECONOMIC ASSOC. 2001: 200–205
  • Information and competition in US forest service timber auctions JOURNAL OF POLITICAL ECONOMY Athey, S., Levin, J. 2001; 109 (2): 375-417